Voyager Therapeutics
Open
$3.74
Prev. Close
$3.74
High
$3.74
Low
$3.72
Market Snapshot
$202.38M
-1.7
-1.14
$80M
141
Voyager Therapeutics, Inc. is a clinical-stage gene therapy company, which engages in the development of treatments for severe neurological diseases. The company is headquartered in Lexington, Massachusetts and currently employs 141 full-time employees. The company went IPO on 2015-11-11. The Company’s pipeline includes programs for Alzheimer’s disease, Friedreich’s ataxia, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and multiple other diseases of the central nervous system. Many of its programs are derived from its Tropism Redirection of AAV by Cell-type-specific Expression of RNA (TRACER) adeno-associated virus (AAV) capsid discovery platform, which is used to generate capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Its pipeline of programs includes Anti-Tau Antibody (VY7523), Tau Silencing Gene Therapy (VY1706), SOD1 Silencing Gene Therapy Program, Vectorized Anti-Amyloid Antibody Early Research Program, Friedreich’s Ataxia Program: VY-FXN01, GBA1 Gene Replacement Program, HD Program and others.
emptyResult
Voyager Therapeutics, Inc. is a clinical-stage gene therapy company, which engages in the development of treatments for severe neurological diseases. The company is headquartered in Lexington, Massachusetts and currently employs 141 full-time employees. The company went IPO on 2015-11-11. The Company’s pipeline includes programs for Alzheimer’s disease, Friedreich’s ataxia, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and multiple other diseases of the central nervous system. Many of its programs are derived from its Tropism Redirection of AAV by Cell-type-specific Expression of RNA (TRACER) adeno-associated virus (AAV) capsid discovery platform, which is used to generate capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Its pipeline of programs includes Anti-Tau Antibody (VY7523), Tau Silencing Gene Therapy (VY1706), SOD1 Silencing Gene Therapy Program, Vectorized Anti-Amyloid Antibody Early Research Program, Friedreich’s Ataxia Program: VY-FXN01, GBA1 Gene Replacement Program, HD Program and others.
Recently from Cashu
Voyager Therapeutics Reports Strong Q4 Growth and Advances in Gene Therapy Development
Voyager Therapeutics Advances in Gene Therapy Amid Strong Q4 Performance Voyager Therapeutics showcases robust growth in its Q4 earnings announcement, reflecting the company’s strong commitment to dev…
Voyager Therapeutics Expands Gene Therapy Pipeline with Strong Financial Performance and Strategic Growth
Voyager Therapeutics Advances Gene Therapy Pipeline Amid Strong Financial Position Voyager Therapeutics, a leading player in the biotech sector, showcases its robust financial health and commitment to…
UniQure Faces Regulatory Challenges in Gene Therapy Development Amid Investor Optimism
Navigating the Complexities of Gene Therapy Development: A Challenge for UniQure UniQure encounters significant challenges with the U.S. Food and Drug Administration (FDA) regarding its gene therapy f…
UniQure’s Huntington's Treatment Faces FDA Scrutiny Amid Gene Therapy Regulatory Challenges
Gene Therapy Controversy: UniQure's Huntington's Disease Treatment at a Crossroads UniQure finds itself under intense scrutiny from the U.S. Food and Drug Administration (FDA) regarding its novel gene…